Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347003 | 0.85 | CD274 (0.46) | MAOAMAOBCD274PDCD1LG2VEGFA | |
| SCHEMBL1347002 | 0.77 | CD274 (0.46) | CD274PDCD1LG2VEGFAEGLN1S1PR1 | |
| SCHEMBL1346339 | 0.77 | CD274 (0.42) | CD274PDCD1LG2VEGFAEGLN1S1PR1 | |
| SCHEMBL1346145 | 0.77 | NAAA (0.37) | MAOAMAOBCD274PDCD1LG2VEGFA | |
| SCHEMBL1347268 | 0.76 | MAOB (0.45) | MAOAMAOBCD274PDCD1LG2S1PR1 | |
| SCHEMBL1347100 | 0.75 | MAOA (0.38) | MAOAMAOBCD274PDCD1LG2VEGFA | |
| SCHEMBL1346922 | 0.75 | KDM1A (0.39) | CD274PDCD1LG2NAAAKDM4EALDH1A1 | |
| SCHEMBL1346170 | 0.75 | NAAA (0.36) | MAOAMAOBVEGFAEGLN1NAAA | |
| SCHEMBL1345967 | 0.75 | MAOA (0.37) | MAOAMAOBCD274VEGFAEGLN1 | |
| SCHEMBL1346483 | 0.74 | CD274 (0.47) | CD274PDCD1LG2NPC1RAB9AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | claimed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | claimed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| JP-2007511564-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | claimed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | claimed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-7968592-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | disclosed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | disclosed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | TRPC3, TRPV3, CACNA1D | MAOA 4191/4885MAOB 4150/4885CD274 3979/4885 |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | TRPC3, TRPV3, CACNA1D | MAOA 4191/4885MAOB 4150/4885CD274 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.